ACAMBIS COMPLETES SMALLPOX VACCINE PROGRAMME



about Epidemiology & the department

Epidemiology academic information

Epidemiology faculty

Epidemilogy resources

sites of interest to Epidemiology professionals



Last Updated

27 Aug 2003

Source: Wall Street Journal, August 27, 2003

Acambis Completes Smallpox Vaccine Programme

DOW JONES NEWSWIRES, Edited Press Release

LONDON -- Acambis said Wednesday that it it has successfully completed the production, filling and quality control testing of all 155 million doses of ACAM2000 smallpox vaccine required under its principal contract with the U.S. Centers for Disease Control and Prevention (CDC).

Of these doses, over half have been labelled and delivered to the U.S. stockpile, the company said.

Over the past few months, a series of discussions have been ongoing between the CDC and the U.S. Food and Drug Administration ("FDA") regarding a new label design for the vials of vaccine that have not yet been labelled.

The remaining vials of ACAM2000 vaccine to be labelled with the new design will be released and delivered to the U.S. stockpile in the coming weeks.

Acambis said that methodology of accounting for revenue under this contract is dependent upon delivery and not just completion of manufacture of the vaccine.

Hence, the revenues relating to delivery of these remaining vials of vaccine that had previously been expected in the second quarter of 2003 are now expected to arise in the third and fourth quarters of this year.

Acambis said it is making no change to its 2003 full-year revenue and profits guidance given at the time of its first quarter results statement on May 8.

With publication of its second quarter results statement scheduled for Sep 16 2003, the company also expects to provide an update on the ACAM2000 clinical trial programme.